Contralateral Prophylactic Mastectomy at the Time of Therapeutic Mastectomy for Local Recurrence of Breast Cancer: Influence of Genetic Testing and Other Factors
Journal of Surgical Oncology · 2026-10 · 134 (5) · 664-672
DOI: 10.1002/jso.70339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 21.07.2026. Verfasst von Candice N Santoro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Breast Neoplasms, Prophylactic Mastectomy, Genetic Testing. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute/Mayo Clinic Paul Calabresi Program in Clinical/Translational Research.
Abstract (Originalsprache)
Background and Objectives Surgical management of ipsilateral breast tumor recurrence (IBTR) is often mastectomy. No guidelines specifically address contralateral prophylactic mastectomy (CPM) for this population. We assessed factors associated with CPM at the time of IBTR mastectomy.
Methods
Patients undergoing mastectomy for IBTR (10/2008‐5/2024) were identified. Demographics, tumor characteristics, and treatment details were assessed.
Results
Of the 381 eligible IBTR patients, 221 (58.0%) had a unilateral therapeutic mastectomy and 160 (42.0%) underwent mastectomy with CPM. CPM patients were younger ( p < 0.0001), with lower clinical T category tumors ( p < 0.001) and less HR + HER2‐ invasive disease ( p = 0.004). CPM patients were more likely to undergo germline genetic testing (63.1% vs 41.6%, p < 0.0001) and were twice as likely to have immediate breast reconstruction ( p < 0.0001). On multivariable analysis, younger age, HR‐HER2 + IBTR subtype, pathogenic variants known at the time of surgery (relative to negative testing and/or no genetic testing), immediate breast reconstruction, and prior radiation for index cancer were each associated with CPM (all p < 0.05).
Conclusion
In our series of 381 patients treated with mastectomy for IBTR, 42% also had a CPM. Multiple factors, including age, tumor stage and biology, immediate breast reconstruction, and genetic testing may impact CPM choice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
- Division of General Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
- Current Address: Division of Surgical Oncology and Endocrine Surgery, Phoenix, Arizona, USA.
ORCID-Profile: Mary M Mrdutt
Förderung
- NCI NIH HHS
- National Cancer Institute/Mayo Clinic Paul Calabresi Program in Clinical/Translational Research
Zitieren
APA
Santoro, C. N., Day, C. N., Sturz-Ellis, J. L., Hieken, T. J., & Mrdutt, M. M. (2026). Contralateral Prophylactic Mastectomy at the Time of Therapeutic Mastectomy for Local Recurrence of Breast Cancer: Influence of Genetic Testing and Other Factors. Journal of Surgical Oncology, 134(5), 664-672. https://doi.org/10.1002/jso.70339
Vancouver
Santoro CN, Day CN, Sturz-Ellis JL, Hieken TJ, Mrdutt MM. Contralateral Prophylactic Mastectomy at the Time of Therapeutic Mastectomy for Local Recurrence of Breast Cancer: Influence of Genetic Testing and Other Factors. Journal of Surgical Oncology. 2026;134(5):664-672. doi:10.1002/jso.70339
BibTeX
@article{Santoro2026,
author = {Santoro, Candice N and Day, Courtney N and Sturz-Ellis, Jenna L and Hieken, Tina J and Mrdutt, Mary M},
title = {Contralateral Prophylactic Mastectomy at the Time of Therapeutic Mastectomy for Local Recurrence of Breast Cancer: Influence of Genetic Testing and Other Factors},
journal = {Journal of Surgical Oncology},
year = {2026},
volume = {134},
number = {5},
pages = {664--672},
doi = {10.1002/jso.70339}
}
EUVIMED